Arrowhead Pharmaceuticals, Inc. (ARWR) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • Positive cash flow • Rich valuation ARWR has strong liquidity and positive free cash flow with improving quarterly earnings, but moderate leverage, heavy operating खर्च, and demanding valuation keep the risk-reward profile mixed.
Price Behavior
Key Price Behavior Insights: • Higher-highs trend • Resistance overhead • Volatile rally Support Level: $69–$71 Resistance Level: $73.91–$74.40 ARWR has trended strongly higher over the last month, with higher highs and higher lows, holding support around $69–$71, though near-term resistance sits near $73.91–$74.40 and volatility leaves it vulnerable to a pullback.
Sentiment & News
Key News Insights: • Commercial shift • EMA progress • Analyst support Arrowhead is transitioning toward commercialization as plozasiran gains regulatory momentum in FCS, with supportive clinical data, constructive analyst sentiment, and continued investor interest.
AI Summary
ARWR has evolved from a speculative biotech into an early commercial story with real regulatory validation, cash runway, and positive FCF, but the stock now depends on proving durable REDEMPLO adoption and broader pipeline execution against a valuation that already prices in meaningful success.
Description
Arrowhead Pharmaceuticals is a Pasadena-based biopharmaceutical company, founded in 1989, that develops RNA interference therapeutics for a range of liver, cardiovascular, pulmonary, rare genetic and oncology indications. Its clinical-stage pipeline includes candidates targeting liver-expressed proteins, cardiovascular lipid regulators, pulmonary targets and other disease-specific genes, and the company partners with Janssen and Takeda on several liver-directed programs. Arrowhead also participates in collaborations for subcutaneously administered RNAi candidates for chronic hepatitis B and other externally developed programs.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 4 | Feb 11 | ARWR | Arrowhead Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment. | Closed | -9.6% |
| Dec 2 | Dec 9 | ARWR | Arrowhead Pharmaceuticals, Inc. | Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout. | Closed | +18.8% |